Activating ESR1 mutations in hormone-resistant metastatic breast cancerDan R. Robinson, Arul M. Chinnaiyan, Yi-Mi Wu et al.|Nature Genetics|2013Cited by 1.2k
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, Nancy U. Lin et al.|Cancer Research|2021Cited by 88
Fever and Neutropenia Clinical Practice Guidelines in OncologyAlison G. Freifeld, Brahm H. Segal, Lindsey R. Baden et al.|Journal of the National Comprehensive Cancer Network|2004Cited by 29